These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 30754964)

  • 1. Cellular immunotherapy in multiple myeloma.
    Vo MC; Lakshmi TJ; Jung SH; Cho D; Park HS; Chu TH; Lee HJ; Kim HJ; Kim SK; Lee JJ
    Korean J Intern Med; 2019 Sep; 34(5):954-965. PubMed ID: 30754964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAR T and CAR NK cells in multiple myeloma: Expanding the targets.
    Shah UA; Mailankody S
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101141. PubMed ID: 32139020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy.
    Alfarra H; Weir J; Grieve S; Reiman T
    Front Immunol; 2020; 11():575609. PubMed ID: 33304346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic cancer/testis antigens are a hallmarker of cancer and a sensible target for cancer immunotherapy.
    Yang P; Meng M; Zhou Q
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188558. PubMed ID: 33933558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.
    Ma T; Shi J; Liu H
    Ann Hematol; 2019 Apr; 98(4):813-822. PubMed ID: 30693373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging Agents.
    Madduri D; Dhodapkar MV; Lonial S; Jagannath S; Cho HJ
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):537-544. PubMed ID: 31427259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DC in multiple myeloma immunotherapy.
    Turtle CJ; Brown RD; Joshua DE; Hart DN
    Cytotherapy; 2004; 6(2):128-37. PubMed ID: 15203989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
    Podar K; Jager D
    Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendritic Cells and Their Role in Immunotherapy.
    Gardner A; de Mingo Pulido Á; Ruffell B
    Front Immunol; 2020; 11():924. PubMed ID: 32508825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy in multiple myeloma--possibility or probability?
    Harrison SJ; Cook G
    Br J Haematol; 2005 Aug; 130(3):344-62. PubMed ID: 16042684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-mediated and cellular immunotherapy in multiple myeloma.
    Ritchie DS; Quach H; Fielding K; Neeson P
    Immunotherapy; 2010 Mar; 2(2):243-55. PubMed ID: 20635931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular immunotherapy as a therapeutic approach in multiple myeloma.
    Liegel J; Avigan D; Rosenblatt J
    Expert Rev Hematol; 2018 Jul; 11(7):525-536. PubMed ID: 29856648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCMA-targeting approaches for treatment of multiple myeloma.
    Chen Y; Nagarajan C; Tan MS; Martinelli G; Cerchione C
    Panminerva Med; 2021 Mar; 63(1):28-36. PubMed ID: 32955181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for the treatment of multiple myeloma.
    Jung SH; Lee HJ; Vo MC; Kim HJ; Lee JJ
    Crit Rev Oncol Hematol; 2017 Mar; 111():87-93. PubMed ID: 28259300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetically modified immune cells targeting tumor antigens.
    Poorebrahim M; Abazari MF; Sadeghi S; Mahmoudi R; Kheirollahi A; Askari H; Wickström SL; Poortahmasebi V; Lundqvist A; Kiessling R; Cid-Arregui A
    Pharmacol Ther; 2020 Oct; 214():107603. PubMed ID: 32553789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendritic cells in pancreatic cancer immunotherapy: Vaccines and combination immunotherapies.
    Yang J; Shangguan J; Eresen A; Li Y; Wang J; Zhang Z
    Pathol Res Pract; 2019 Dec; 215(12):152691. PubMed ID: 31676092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor T cell therapies for multiple myeloma.
    Wu C; Zhang L; Brockman QR; Zhan F; Chen L
    J Hematol Oncol; 2019 Nov; 12(1):120. PubMed ID: 31752943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Immune Therapies for Myeloma.
    Rosenblatt J; Avigan D
    J Natl Compr Canc Netw; 2015 Nov; 13(11):1440-7. PubMed ID: 26553769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current developments in immunotherapy in the treatment of multiple myeloma.
    Köhler M; Greil C; Hudecek M; Lonial S; Raje N; Wäsch R; Engelhardt M
    Cancer; 2018 May; 124(10):2075-2085. PubMed ID: 29409124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.